New study reveals how sugammadex works in obese patients during surgery
NCT ID NCT05328778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 trial studied how sugammadex, a drug that reverses muscle relaxants, works in 48 patients undergoing laparoscopic surgery. Researchers measured drug levels in the blood and how quickly patients recovered muscle function. The study focused on patients with a BMI of 25 or higher who were having bariatric surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sugammadex (a drug that reverses muscle relaxants used during surgery)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, 510010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New painkiller injection could cut opioid use after chest surgery